What Damora Therapeutics does

Damora Therapeutics (NASDAQ: DMRA) is a pre-revenue, clinical-stage biotechnology company headquartered in the Boston area and domiciled in Massachusetts, developing a new generation of disease-modifying monoclonal antibody biologics targeting mutant calreticulin (mutCALR), the disease driver in approximately 25% of essential thrombocythemia and 35% of myelofibrosis cases, a U.S. patient population of roughly 42,000. The lead asset, DMR-001, is engineered for exclusive mutCALR binding, with preclinical data showing approximately 10-fold potency gain against Type 2 mutant cells and approximately 5-fold half-life extension versus a relevant reference antibody, enabling subcutaneous autoinjector administration. The pipeline contains four programs (DMR-001 through DMR-004) using diverse modalities across the Type 1 and Type 2 CALR mutation spectrum, with regulatory submission for DMR-001 planned for mid-2026 and proof-of-concept clinical datasets expected beginning mid-2027.

The company was formed via Galecto, Inc.'s November 2025 acquisition of the original Damora Therapeutics and a concurrent oversubscribed private placement of approximately $284.9 million, followed by rebranding from Galecto to Damora and a $316 million public offering in March 2026. The cash position was approximately $532.9 million as of March 31, 2026, funding operations into 2029. Leadership is anchored by CEO Jennifer Jarrett (former COO/CFO of Arcus Biosciences, CFO of Medivation) alongside several former Blueprint Medicines executives (COO Sherwin Sattarzadeh, CMO Dr. Becker Hewes, CCO Jim Baker) and a board chaired by Peter Harwin of Fairmount Funds Management.

The business model is contingent on regulatory approval. Planned go-to-market channels include pharmaceutical distribution through specialty pharmacies, hospital buying groups, and academic medical centers, leveraging the subcutaneous autoinjector format for patient self-administration. Pricing has not been publicly disclosed. Sell-side analysts at TD Cowen, RBC Capital, Evercore ISI, and Leerink project peak sales of approximately $3.3 billion for DMR-001 in myelofibrosis and $3 billion in essential thrombocythemia. FY2025 net loss was approximately $209.84 million and Q1 2026 net loss was $27.8 million, reflecting elevated R&D investment ahead of clinical trials.

Name

Damora Therapeutics

Legal name

Damora Therapeutics, Inc.

Website

https://damoratx.com

Company type

Public

Founded year

2025

Operating status

Operating

Short description

Damora Therapeutics is a pre-revenue, clinical-stage biotechnology company developing monoclonal antibody biologics targeting mutant calreticulin for the treatment of mutant CALR-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), serving an addressable U.S. population of approximately 42,000 patients.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)

Keywords

• Monoclonal antibody therapy
• Myeloproliferative neoplasm treatment
• Rare disease biologics
• Oncology drug development
• Calreticulin targeted therapeutics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Damora Therapeutics is a pre-revenue biotechnology company that has not yet commercialized any products. The company is developing DMR-001 and additional pipeline assets for mutant CALR-driven myeloproliferative neoplasms. Upon regulatory approval, the company plans to generate revenue through the sale of pharmaceutical products, initially focusing on the U.S. market with plans for global expansion through clinical development.
2. Potential Licensing and Partnership Revenue: As a development-stage biotech company, Damora may pursue licensing agreements, co-development partnerships, or strategic collaborations to advance its pipeline and generate revenue. TD Cowen coverage cited $3.3 billion peak sales forecast for DMR-001 in myelofibrosis and $3 billion in essential thrombocythemia, indicating significant commercial potential.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Damora Therapeutics develops a pipeline of investigational monoclonal antibody therapeutics designed to exclusively target mutant calreticulin (mutCALR) for the treatment of myeloproliferative neoplasms, specifically Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is engineered with clinically validated half-life extension technology to enable convenient, infrequent subcutaneous administration via autoinjector, offering a first-in-class disease-modifying approach for approximately 42,000 U.S. patients with no currently approved targeted therapy available.

Product overview

Damora Therapeutics is developing a pipeline of targeted biologics (monoclonal antibodies) for mutant calreticulin-driven myeloproliferative neoplasms (MPNs). The company's lead asset is DMR-001, an investigational monoclonal antibody therapy targeting mutCALR with best-in-class potential. The pipeline includes multiple programs (DMR-001, DMR-002, DMR-003, DMR-004) all targeting the same disease driver but leveraging diverse modalities to address the full spectrum of MPN patients. DMR-001 is the most advanced, with plans for regulatory submission in mid-2026 and Phase 1/1b clinical trial initiation, with proof-of-concept data expected beginning mid-2027.

Differentiator

Problem solved

Functional benefit

Products and services

• DMR-001 DMR-001 is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR) with best-in-class potential for treating Essential Thrombocythemia (ET) and Myelofibrosis (MF). It is engineered for high selectivity and potency, with extended half-life to enable convenient, infrequent subcutaneous administration via autoinjector. Preclinical data show approximately 10-fold higher potency against Type 2 mutant cells and approximately 5-fold longer half-life compared to a reference antibody. Damora plans regulatory submission in mid-2026 to enable a global Phase 1/1b trial, with proof-of-concept data expected beginning in mid-2027.
• DMR-002 DMR-002 is the second program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through a distinct modality from DMR-001, progressing through discovery and IND-enabling stages toward clinical development to address the full spectrum of MPN patients.
• DMR-003 DMR-003 is the third program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through an additional modality to provide portfolio optionality across the full spectrum of MPN patients.
• DMR-004 DMR-004 is the fourth program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through an additional modality to provide portfolio optionality across the full spectrum of MPN patients.

Quantifiable outcome

• 10-fold increase in potency against Type 2 mutant cells compared to reference antibody
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Arcus BiosciencesminorStrategic or Co-development Partner · 23 March 2026CEO Jennifer Jarrett previously served as COO and CFO at Arcus Biosciences. While not an active partnership, this represents the executive's background and potential network connection to another oncology-focused biotechnology company.
• Galecto, Inc.coreStrategic or Co-development Partner · 9 November 2025Galecto, Inc. acquired Damora Therapeutics, Inc., with Damora subsequently rebranding from Galecto Inc. The acquisition brought mutant calreticulin-targeted therapies for rare blood cancers under the Damora name. Following the acquisition, Damora secured approximately $284.9 million through an oversubscribed private placement and $316 million public offering to fund operations and pipeline development.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Disc Medicine: Disc Medicine is a clinical-stage hematology company developing therapeutics for serious hematologic diseases, including programs targeting erythropoietic protoporphyria and other rare blood disorders. It represents an emerging player in the rare blood disease space with comparable clinical-stage positioning.
• Geron Corporation: Geron markets imetelstat (Rytelo) for transfusion-dependent anemia in lower-risk MDS, with development programs extending into myelofibrosis. As a hematology-focused emerging player with a recently approved oncology product, Geron is a comparable clinical-to-commercial stage MPN competitor.
• Syndax Pharmaceuticals: Syndax is a clinical-stage oncology company developing axatilimab for chronic graft-versus-host disease and other hematology indications. CEO Jennifer Jarrett serves on Syndax's board, and the company represents a comparable clinical-stage hematology/oncology peer in size and stage.
• MorphoSys (now part of Novartis): MorphoSys (acquired by Novartis) acquired Constellation Pharmaceuticals and developed pelabresib (CPI-0610) for myelofibrosis as a BET inhibitor. As a developer of novel MPN therapies, it represents a comparable clinical-stage player in the same disease space.

Others

• Ionis Pharmaceuticals: Ionis is an established RNA-targeted therapeutics platform company with development programs in hematology/oncology. While not directly competing in MPNs, Ionis represents a comparable biologics-platform biotech with expertise in targeted therapeutics development for rare diseases.
• Blueprint Medicines: Blueprint Medicines is the prior employer of much of Damora's leadership team (CEO Jarrett, COO Sattarzadeh, CMO Hewes, CCAO Baker) and developed AYVAKIT for systemic mastocytosis. While not directly competing in MPNs, Blueprint is a strategic comparator in rare hematology/oncology drug development.

Broad incumbents

• Bristol-Myers Squibb: BMS markets fedratinib (Inrebic) for myelofibrosis, directly competing in the MPN market. As a large pharmaceutical incumbent with established hematology/oncology commercial infrastructure, BMS is a significant competitor for Damora's DMR-001 in the same indication.

Direct peers

• GSK (Sierra Oncology): GSK acquired Sierra Oncology and markets momelotinib (Omjjara) for myelofibrosis, a direct competitor to DMR-001 in the same patient population. The presence of multiple JAK inhibitors in MF demonstrates the competitive landscape Damora will face at launch.
• Sobi (Swedish Orphan Biovitrum): Sobi acquired CTI BioPharma and markets pacritinib (Vonjo) for myelofibrosis patients with severe thrombocytopenia, a direct competitor in the MF space. Sobi represents a direct peer with a marketed MPN product and established rare disease commercial infrastructure.
• Incyte: Incyte's ruxolitinib (Jakafi) is the leading approved therapy for myelofibrosis, making Incyte the dominant direct competitor in the MPN space. Damora's DMR-001 will be evaluated against this established standard of care in the same patient population.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/damora-therapeutics/jobs

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Damora Therapeutics